SG Americas Securities LLC decreased its holdings in shares of Cambrex Co. (NYSE:CBM) by 6.0% during the 3rd quarter, Holdings Channel.com reports. The fund owned 39,483 shares of the biotechnology company’s stock after selling 2,521 shares during the period. SG Americas Securities LLC’s holdings in Cambrex were worth $2,349,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Marshall Wace LLP acquired a new stake in shares of Cambrex in the first quarter valued at approximately $30,000. Quantamental Technologies LLC bought a new stake in Cambrex during the second quarter worth approximately $100,000. Tower Research Capital LLC TRC boosted its holdings in Cambrex by 67.7% during the second quarter. Tower Research Capital LLC TRC now owns 2,188 shares of the biotechnology company’s stock worth $102,000 after buying an additional 883 shares in the last quarter. Yorktown Management & Research Co Inc bought a new stake in Cambrex during the third quarter worth approximately $250,000. Finally, Magnus Financial Group LLC acquired a new position in Cambrex in the 2nd quarter worth approximately $215,000.
A number of research firms recently commented on CBM. Zacks Investment Research lowered shares of Cambrex from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. William Blair lowered shares of Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 price objective for the company. in a research note on Wednesday, August 7th. ValuEngine lowered shares of Cambrex from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 9th. Finally, Craig Hallum lowered shares of Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price objective for the company. in a research note on Monday, August 12th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $54.83.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Further Reading: What is a Futures Contract?
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.